Nail Psoriasis: An Updated Review and Expert Opinion on Available Treatments, Including Biologics

被引：39

作者：

Bardazzi, Federico ^{[1
]}

Starace, Michela ^{[1
]}

Bruni, Francesca ^{[1
]}

Magnano, Michela ^{[1
]}

Piraccini, Bianca Maria ^{[1
]}

Alessandrini, Aurora ^{[1
]}

机构：

[1] Univ Bologna, Dept Expt Diagnost & Specialty Med, Div Dermatol, Via Massarenti 1, IT-40138 Bologna, Italy

来源：

ACTA DERMATO-VENEREOLOGICA | 2019年 / 99卷 / 06期

关键词：

biologic therapy; efficacy; nail psoriasis; systemic therapy; tolerability; TO-SEVERE PSORIASIS; OPTICAL COHERENCE TOMOGRAPHY; BETAMETHASONE DIPROPIONATE; CLINICAL PRESENTATION; PLAQUE PSORIASIS; EFFICACY; ARTHRITIS; MODERATE; ADALIMUMAB; THERAPY;

D O I：

10.2340/00015555-3098

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Nail psoriasis affects 50-79% of patients with skin psoriasis and up to 80% of patients with psoriatic arthritis, and can also represent a negative prognostic factor in individuals with plaque psoriasis. Treatments for nail psoriasis are limited, as nails are often difficult to treat with topical therapies alone, and relapse is common. Among different systemic agents, secukinumab, a fully human monoclonal antibody targeting interleukin (IL)-17A, is the only antibody supported by a trial specifically conducted in patients with nail psoriasis (the TRANSFIGURE trial) and has the longest follow-up available to date. In this setting, secukinumab is characterized by the highest efficacy at week 16. This review analysed the different therapeutic options for nail psoriasis, focusing on new treatments that have shown promising results in this field.

引用

页码：516 / 523

页数：8

共 60 条

[1]

Armstrong April W, 2016, J Clin Aesthet Dermatol, V9, pS12

[2] Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes [J].